Non-Small Cell Lung Cancer Clinical Trials

A listing of 148 Non-Small Cell Lung Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Non-Small Cell Lung Cancer

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 148 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and New York.

Featured Trial

RSV Vaccine For Adults With Kidney, Liver or Lung Transplant

Recruiting

The RSVoice Trial is a Phase 3 clinical trial conducted by Moderna to evaluate the safety and immune response of an investigational vaccine aimed at preventing respiratory syncytial virus (RSV) infection in adults who have received a kidney, liver, or lung transplant.

Conditions:

Kidney Transplantation

Kidney Transplant

Liver Transplantation

Lung Transplantation

Chronic Kidney Disease

Learn More

Featured Trial

Non-Small Cell Lung Cancer Treatment

Recruiting

A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations

Conditions:

NSCLC

Lung Cancer

Non-Small Cell Lung Cancer

Carcinoma

Non-Small-Cell Lung

Learn More

Intratumoral Cisplatin for Resectable NSCLC

NCT04809103

Recruiting

PRIMARY OBJECTIVE: To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol DESIGN: 3+3 dose escalation.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/20/2022

Locations: University of Vermont, Burlington, Vermont

Conditions: Non-Small Cell Lung Cancer

Learn More ›

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

NCT04052412

Recruiting

This study is to assess the biodistribution and kinetics of a novel T-cell imaging agent in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy. This study is assessing the change in kinetics that occurs in this patient population to better understand the distribution of this compound in patient disease circumstances.

Gender:

All

Ages:

21 years and above

Trial Updated:

05/12/2022

Locations: University of Tennessee Medical Center, Knoxville, Tennessee

Conditions: Non-small Cell Lung Cancer

Learn More ›

Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC

NCT05094544

Recruiting

The current proposal is structured as a pilot trial to evaluate the impact of non-ablative SBRT (800 cGy X 3 fractions) as an immunomodulatory mechanism in patients with early stage NSCLC who are surgical candidates. Tumor, normal tissue and blood specimens will be analyzed for immunomodulatory changes including phenotypic changes in tumor cell surface marker expression, tumor and normal tissue microenvironment and gene expression profiles, serum/blood immune profile changes, and circulating tumor cell immunophenotypic and gene expression alterations. Published literature showed that cytotoxic doses of XRT may not elicit a clinically meaningful alteration in the immune profile. Further, studies using an animal model have concluded a fractionated regimen induces a greater abscopal effect than single dose radiation. Furthermore, research has shown a regimen of 800 cGy X 3 fractions yielded the most significant changes in the immune profile compared to 2000 cGy X 1 or 600 cGy X 5. The immune response within the tumor milieu is a complex dynamic process with an interplay among lymphocyte subsets, antigen presenting cells/dendritic cells, macrophages, and tumor cells. The interactions between the various components is orchestrated by a variety of extracellular and intracellular signaling pathways involving ligand and cell surface expression, cytokine release, and activation or inhibition of a variety of T cell subsets. In order to comprehensively define the immunomodulatory effect of three fractions of 800 cGy on the primary tumor, the investigators will analyze the following: tumor cell surface phenotype, tumor microenvironment immune profile and gene expression profile, T cell repertoire changes in tumor tissue and peripheral blood, and circulating tumor cell phenotype and gene expression profiles. Each of these components has been shown to be impacted by radiation in either a cell culture or animal model systems. By characterizing, quantitating and defining these changes related to three fractions of 800 cGy, it will directly provide important insights to inform rational uses of XRT and immunotherapy in the future. Read Less

Gender:

All

Ages:

18 years and above

Trial Updated:

03/21/2022

Locations: University of Kansas Medical Center, Kansas City, Kansas

Conditions: Non-small Cell Lung Cancer

Learn More ›

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

NCT04045496

Recruiting

This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/13/2022

Locations: HealthONE Clinic Services Oncology-Hematology, Denver, Colorado +3 locations

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors

Learn More ›